Therapeutic blockade of inhibitory immune checkpoint pathways (e.g., PD-1/PD-L1 and CTLA-4) has transformed the care of patients across multiple cancer types, including many formerly intractable advanced cancers (1). This evidence concerns the gene CTLA4 and cancer.